Skip to main content

This job has expired

You will need to login before you can apply for a job.

Scientist, Gene Editing Platform Development

Employer
Intellia Therapeutics
Location
Cambridge, MA
Start date
Feb 6, 2023

Job Details

Why Join Intellia?

Our mission is to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

Beyond our science, we live our four core values: One, Explore, Disrupt, Deliver and feel strongly that you can achieve more at Intellia. We have a single-minded determination to excel and succeed together. We believe in the power of curiosity and pushing boundaries. We welcome challenging thoughts and imagination to develop innovative solutions. And we know that patients are counting on us to make the promise a reality, so we must maintain high standards and get it done.

We wantall ofour people to go beyond what is possible. We aren’t constrained by typical end rails, and we aren’t out to just “treat” people. We’re all in this for something more. We’re driven to cure and motivated for change. Just imagine the possibilities of what we can do together.

How you will Achieve More with Intellia:

We are looking for a Scientist to join our energetic, exciting, and cross-functional team. You will be responsible for helping drive emerging gene-editing technologies towards human therapeutics. You will evaluate new technologies and approaches to support Intellia’s Gene Editing Platform Development. Additional role responsibilities include:

  • Design, execute and troubleshoot high throughput experiments to optimize gene editing efficiency in different mammalian immortal cell lines and primary cells via different delivery methods (Lentivirus, AAV, Lipid nanoparticles etc.)

  • Perform experiments using multiple instruments to measure mRNA and protein expression (RT-PCR, ELISA, Immunofluorescence, Flow-cytometry etc.) and/or genome integrity (digital droplet PCR, Next-generation sequencing etc.)

  • Integrate mechanistic understanding on the biochemical and cellular level to drive direction of projects

  • Act as a liaison and collaborate in a matrixed organization to optimize gene editing efficiency in different animal and disease models

  • Document results in a timely manner in electronic notebooks and present data internally and with external collaborators.

  • Analyze and synthesize results to assess future directions

About You:

Do you describe yourself as high-energy and goal-driven? Our ideal candidate will have extensive experience with different CRISPR-based gene editing technologies. Expertise with a broad spectrum of molecular biology, cell biology, and biochemical methodologies are also required. Additional role requirements include:

  • Organized, driven self-starter with demonstrated problem-solving skills and the ability to work effectively within a broader cross-functional team

  • PhD (2-4 years) in Biochemistry, Biophysics or Cellular and Molecular biology. Strong candidates with Bachelors (6-8 years) or Masters (4-6 years) in related disciplines will also be considered.

  • Extensive knowledge of the CRISPR landscape and experience in mammalian genome editing with CRISPR/Cas9 or similar technologies.

  • Experience with rational design and/or directed evolution of proteins and/or nucleic acids

Meet your future team:

The Gene Editing Platform Development team, within the Platform Innovation function, is a cohesive group of fun and energetic individuals. We have a common goal of making a difference by developing new and improved CRISPR-based gene editing tools for curative human therapeutics. You will report directly to Sr. Scientist, Gene Editing Platform Innovation. This hiring manager leads a sub-team within the engineering group geared towards expanding Intellia’s gene editing toolbox to potentially unlock currently inaccessible disease indications. Given the breadth of activities within this team, the candidate will have the opportunity to explore both new and established projects across Intellia’s in vivo and ex vivo platforms and programs.

The team is currently working mostly onsite to execute workflows in a wet-lab environment. Therefore, we require the candidate to be currently local to Cambridge MA, or open to relocating. While much of the day-to-day operations require wet-lab work, our team is focused on building not just technical expertise but fostering an environment for growth of scientists interested in a career in biotech and chemistry. If you join our team, you can expect to join a hardworking and collaborative environment. We look forward to fostering your skills, learning from your experiences, and building a larger team that will make a difference in patient’s lives.

#LI-KO1

Covid-19 Vaccination Policy: All Intellia employees, regardless of work location, must be fully vaccinated for COVID-19. This requirement includes a booster dose once eligible. Requests for exemption for medical or sincerely held religious beliefs will be considered.

EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.

Company

Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
 
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
 
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

Change life stories with genome editing therapies!

Stock Symbol: NTLA

TwitterInstagram

Company info
Website
Phone
(857) 285-6200
Location
40 Erie Street
Cambridge
Massachusetts
02139
United States

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert